Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Am J Pathol. 1997 Dec; 151(6): 1655–1661.
PMCID: PMC1858342
PMID: 9403716

Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells.

Abstract

We examined the role of urokinase-type plasminogen activator (u-PA) in the metastasis of the human renal cell carcinoma (HRCC) implanted in athymic nude mice. Cells from a HRCC KG-2 line were implanted in orthotopic (kidney) and ectopic (subcutaneous) organs. The KG-2 cells implanted in the kidney produced local tumors and lung metastases, whereas those implanted subcutaneously produced only local tumors. The production of u-PA was determined by immunohistochemistry and an enzyme-linked immunosorbent assay (ELISA). High levels of u-PA were produced by the metastatic kidney tumors and lung metastases, whereas the subcutaneous tumors produced low levels. KG-2 cells co-cultured with mouse kidney or lung fibroblasts produced higher levels of u-PA than KG-2 cells co-cultured with mouse skin fibroblasts. Furthermore, KG-2 cells cultured with the conditioned medium from mouse kidney or lung fibroblasts produced higher levels of u-PA than KG-2 cells cultured with the conditioned medium from mouse skin fibroblasts. The results indicate that the expression of u-PA by KG-2 cells is one of the important factors that determine their metastatic potential and that the production of u-PA is influenced by the organ microenvironment, including soluble factors produced by surrounding fibroblasts.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  • Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1990 Oct 1;50(19):6130–6138. [PubMed] [Google Scholar]
  • Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 1986 Aug;46(8):4109–4115. [PubMed] [Google Scholar]
  • Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541–573. [PubMed] [Google Scholar]
  • Tryggvason K, Höyhtyä M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta. 1987 Nov 25;907(3):191–217. [PubMed] [Google Scholar]
  • Salo T, Liotta LA, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggvason K. Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis. Int J Cancer. 1982 Nov 15;30(5):669–673. [PubMed] [Google Scholar]
  • Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. [PubMed] [Google Scholar]
  • Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst. 1990 Dec 19;82(24):1890–1898. [PubMed] [Google Scholar]
  • Gohji K, Nakajima M, Fabra A, Bucana CD, von Eschenbach AC, Tsuruo T, Fidler IJ. Regulation of gelatinase production in metastatic renal cell carcinoma by organ-specific fibroblasts. Jpn J Cancer Res. 1994 Feb;85(2):152–160. [PMC free article] [PubMed] [Google Scholar]
  • Darras V, Thienpont M, Stump DC, Collen D. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemost. 1986 Dec 15;56(3):411–414. [PubMed] [Google Scholar]
  • Fabra A, Nakajima M, Bucana CD, Fidler IJ. Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. Differentiation. 1992 Dec;52(1):101–110. [PubMed] [Google Scholar]
  • Nakajima M, Chop AM. Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Semin Cancer Biol. 1991 Apr;2(2):115–127. [PubMed] [Google Scholar]
  • Sappino AP, Busso N, Belin D, Vassalli JD. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res. 1987 Aug 1;47(15):4043–4046. [PubMed] [Google Scholar]
  • Yamamoto M, Sawaya R, Mohanam S, Bindal AK, Bruner JM, Oka K, Rao VH, Tomonaga M, Nicolson GL, Rao JS. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res. 1994 Jul 15;54(14):3656–3661. [PubMed] [Google Scholar]
  • Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, Klijn JG. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 1992 Nov 1;52(21):6101–6105. [PubMed] [Google Scholar]
  • Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D, Rabbani SA. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 1994 May 1;54(9):2372–2377. [PubMed] [Google Scholar]
  • Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 1994 Dec 15;54(24):6539–6548. [PubMed] [Google Scholar]
  • Boyd D, Ziober B, Chakrabarty S, Brattain M. Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma. Cancer Res. 1989 Feb 15;49(4):816–820. [PubMed] [Google Scholar]
  • Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol. 1989 Jul;142(1):193–198. [PubMed] [Google Scholar]
  • Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer. 1992 Apr 1;50(6):871–873. [PubMed] [Google Scholar]
  • Cajot JF, Sordat B, Bachmann F. Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment. J Natl Cancer Inst. 1986 Nov;77(5):1099–1107. [PubMed] [Google Scholar]
  • Schor SL, Schor AM. Clonal heterogeneity in fibroblast phenotype: implications for the control of epithelial-mesenchymal interactions. Bioessays. 1987 Nov;7(5):200–204. [PubMed] [Google Scholar]
  • Lengyel E, Gum R, Juarez J, Clayman G, Seiki M, Sato H, Boyd D. Induction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res. 1995 Feb 15;55(4):963–967. [PubMed] [Google Scholar]
  • Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 1991 Jul 15;51(14):3753–3761. [PubMed] [Google Scholar]
  • Collart MA, Belin D, Vassalli JD, de Kossodo S, Vassalli P. Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J Exp Med. 1986 Dec 1;164(6):2113–2118. [PMC free article] [PubMed] [Google Scholar]
  • Jensen PJ, Rodeck U. Autocrine/paracrine regulation of keratinocyte urokinase plasminogen activator through the TGF-alpha/EGF receptor. J Cell Physiol. 1993 May;155(2):333–339. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

-